Early Treatment of COVID-19 Disease: A Missed Opportunity
Abstract Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of disease, reducing morbidity, mortality, and the likelihood of onward transmission. At the time of writing, more than 1900 clinical trials are registered globally to assess the efficacy and safety...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2020-10-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-020-00349-8 |
| _version_ | 1831664259566665728 |
|---|---|
| author | Jamie I. Forrest Craig R. Rayner Jay J. H. Park Edward J. Mills |
| author_facet | Jamie I. Forrest Craig R. Rayner Jay J. H. Park Edward J. Mills |
| author_sort | Jamie I. Forrest |
| collection | DOAJ |
| description | Abstract Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of disease, reducing morbidity, mortality, and the likelihood of onward transmission. At the time of writing, more than 1900 clinical trials are registered globally to assess the efficacy and safety of candidate therapeutics for COVID-19. The majority of these trials are designed to evaluate the comparative efficacy and safety of candidate therapeutics for the treatment of COVID-19 to prevent death among populations of hospitalized patients with advanced disease. Yet, emerging epidemiological evidence now indicates that the majority of those infected with the SARS-CoV-2, while still infectious, experience minimal or mild disease symptomology. Like HIV and hepatitis C that pioneered treatment as prevention, there is a missed opportunity for trials of early pharmaceutical intervention for COVID-19 disease evaluating not only reductions in morbidity and mortality but also transmissibility. We discuss this clinical research gap within an historical context of viral treatment as prevention for HIV and hepatitis C, and comment on the challenges and opportunities for clinical research of candidate therapeutics for early COVID-19 disease. |
| first_indexed | 2024-12-19T19:12:07Z |
| format | Article |
| id | doaj.art-8c61aa5422a14a1782d4df8923662dec |
| institution | Directory Open Access Journal |
| issn | 2193-8229 2193-6382 |
| language | English |
| last_indexed | 2024-12-19T19:12:07Z |
| publishDate | 2020-10-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj.art-8c61aa5422a14a1782d4df8923662dec2022-12-21T20:09:15ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822020-10-019471572010.1007/s40121-020-00349-8Early Treatment of COVID-19 Disease: A Missed OpportunityJamie I. Forrest0Craig R. RaynerJay J. H. Park1Edward J. Mills2Cytel Canada Health Inc.Cytel Canada Health Inc.Cytel Canada Health Inc.Abstract Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of disease, reducing morbidity, mortality, and the likelihood of onward transmission. At the time of writing, more than 1900 clinical trials are registered globally to assess the efficacy and safety of candidate therapeutics for COVID-19. The majority of these trials are designed to evaluate the comparative efficacy and safety of candidate therapeutics for the treatment of COVID-19 to prevent death among populations of hospitalized patients with advanced disease. Yet, emerging epidemiological evidence now indicates that the majority of those infected with the SARS-CoV-2, while still infectious, experience minimal or mild disease symptomology. Like HIV and hepatitis C that pioneered treatment as prevention, there is a missed opportunity for trials of early pharmaceutical intervention for COVID-19 disease evaluating not only reductions in morbidity and mortality but also transmissibility. We discuss this clinical research gap within an historical context of viral treatment as prevention for HIV and hepatitis C, and comment on the challenges and opportunities for clinical research of candidate therapeutics for early COVID-19 disease.https://doi.org/10.1007/s40121-020-00349-8Clinical trialsCOVID-19Early treatmentTreatment as prevention |
| spellingShingle | Jamie I. Forrest Craig R. Rayner Jay J. H. Park Edward J. Mills Early Treatment of COVID-19 Disease: A Missed Opportunity Infectious Diseases and Therapy Clinical trials COVID-19 Early treatment Treatment as prevention |
| title | Early Treatment of COVID-19 Disease: A Missed Opportunity |
| title_full | Early Treatment of COVID-19 Disease: A Missed Opportunity |
| title_fullStr | Early Treatment of COVID-19 Disease: A Missed Opportunity |
| title_full_unstemmed | Early Treatment of COVID-19 Disease: A Missed Opportunity |
| title_short | Early Treatment of COVID-19 Disease: A Missed Opportunity |
| title_sort | early treatment of covid 19 disease a missed opportunity |
| topic | Clinical trials COVID-19 Early treatment Treatment as prevention |
| url | https://doi.org/10.1007/s40121-020-00349-8 |
| work_keys_str_mv | AT jamieiforrest earlytreatmentofcovid19diseaseamissedopportunity AT craigrrayner earlytreatmentofcovid19diseaseamissedopportunity AT jayjhpark earlytreatmentofcovid19diseaseamissedopportunity AT edwardjmills earlytreatmentofcovid19diseaseamissedopportunity |